SynthesisBMC infectious diseases2025
Immunogenicity and safety of the domestic and imported live-attenuated varicella vaccine in healthy Chinese populations: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of two-dose varicella vaccination in Guangzhou: An interrupted time-series study.Human vaccines & immunotherapeutics · 2026Article
- Genomic comparison reveals single-nucleotide polymorphic sites and attenuation-associated site combinations specific to Chinese live attenuated varicella-zoster virus vaccines.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesThis study aimed to synthesize existing evidence to compare the immunogenicity and safety of domestic and imported live-attenuated varicella vaccine (VarV) in healthy Chinese populations.
methodsWe searched PubMed, Web of Science, Embase, China National Knowledge Internet (CNKI), Wan Fang Database, and Chinese Biomedical Literature Service System (SinoMed) using predefined search terms to identify relevant studies. Retrieve all language articles up to March 15, 2024. Articles reported varicella vaccination in healthy Chinese populations were included. We calculated the pooled rates of seroconversions and adverse events using the random effects model and assessed the quality of each study using the modified Jadad Scale and Newcastle Ottawa Scale (NOS). Publication bias was evaluated using Egger's regression test.
resultsIn our immunogenicity analysis, which included 16,655 Chinese individuals from 21 studies, the pooled seroconversion rate was 89% (95%CI: 86-91%) for domestic VarV and 93% (95%CI: 88-98%) for imported Varv, with no statistically significant difference. In our safety analysis, which included 29,696 Chinese individuals from 25 studies, the pooled rate of systemic reactions was higher for domestic Varv (11%, 95%CI: 10-13%) than for imported Varv (8%, 95%CI: 6-10%; P < 0.001), while the results for local reactions were the opposite (domestic Varv: 3%, 95%CI: 2-3%; imported Varv: 7%, 95%CI: 3-10%; P = 0.020). The results are based on pooled proportions rather than direct comparison. Egger's test suggested that publication bias was not negligible.
conclusionsBoth domestic and imported varicella vaccines appear to be generally immunogenic and safe in healthy Chinese populations. However, due to limited and heterogeneous data on imported vaccines, further high-quality studies are needed to validate these comparative findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.